Castle Biosciences Inc

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Castle Biosciences posts robust Q4 earnings, eyes growth opportunities ahead

Castle Biosciences reported strong financial performance in Q4 and full-year 2022, driven by revenue growth and test volume increase.
The company's focus on expanding commercial teams, R&D initiatives, and new laboratory openings positions it for future growth.
Challenges lie in convincing commercial payers and maintaining gross margin, requiring strategic actions and evidence-based outcomes.
Opportunities exist in demonstrating patient outcomes, NCCN guideline inclusion, and leveraging cash reserves for growth.

Castle Biosciences reports robust Q1 performance and navigates growth challenges

Castle Biosciences delivered a strong Q1 2023 with notable revenue growth and volume increases, supported by a solid financial position.
The company's focus on dermatology, gastroenterology, and mental health segments, along with positive clinical study results, underpin its market strength.
While facing challenges in sales execution and territory management, Castle Biosciences is strategically positioned to capitalize on growth opportunities in its key product lines.

Castle Biosciences reports robust Q2 growth and navigates coverage challenges

Castle Biosciences delivered strong financial performance in Q2 2023, with revenue and test volume growth surpassing expectations.
Despite challenges in coverage and operational constraints, the company's strategic focus on test value and market expansion presents promising growth prospects.
With a solid financial position, ongoing efforts to address challenges, and capitalize on opportunities, Castle Biosciences is poised for continued success in the precision medicine market.

Castle Biosciences reports stellar Q3 results and eyes market expansion

Castle Biosciences delivered exceptional financial results, raised revenue guidance, and showcased strong growth across its test portfolio. The company's focus on innovation, clinical impact, and market recognition positions it well for future success. While challenges in managing growth and competition exist, Castle Biosciences has opportunities to capitalize on its strengths and expand its market presence.

Castle Biosciences reports stellar 2023 performance and eyes new markets

Castle Biosciences delivered strong financial performance in Q4 and full year 2023, driven by robust revenue growth and impressive test volume results across key tests.
The company showcased clinical efficacy, innovation, and financial discipline, while navigating challenges such as cost pressures and reimbursement uncertainties.
Strategic initiatives like expanding test portfolios, managing costs effectively, and exploring new growth avenues position Castle Biosciences for continued success and market leadership.
With a focus on maintaining profitability, investing in growth, and leveraging opportunities, Castle Biosciences is poised for sustained growth and value creation in the future.

Castle Biosciences excels in Q1 2024, eyes strategic growth opportunities

Castle Biosciences delivered exceptional financial and operational results in Q1 2024, showcasing strong revenue growth, improved margins, and product advancements. While facing some challenges with test volumes and Medicare coverage, the company's solid performance and market position present promising opportunities for future growth.

Castle Biosciences excels in Q2, raises guidance amid test volume surge

Castle Biosciences delivered outstanding financial results in Q2 2024, showcasing strong revenue growth, improved margins, and a significant net income turnaround.
The company's focus on innovation and clinical value in its tests positions it well for sustained growth and market leadership in precision diagnostics.
While facing challenges in maintaining growth momentum and operational efficiency, Castle Biosciences has opportunities to expand its market presence and drive international expansion.
Overall, Castle Biosciences' Q2 performance reflects a resilient and promising trajectory, underpinned by strategic strengths and a commitment to advancing patient care.

Castle Biosciences excels in Q3, poised for sustained growth

Castle Biosciences' Q3 performance reflects strong revenue growth, financial stability, and a positive outlook for future expansion.
The company's focus on product innovation, market penetration, and financial discipline positions it well for continued success.
While challenges exist in maintaining growth and profitability, Castle Biosciences has ample opportunities for further market expansion and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the fourth quarter and year-ended Dec. 31, 2021, after the close of market on Monday, Feb. 28, 2022.

Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the 11th Annual SVB Leerink Global Healthcare Conference on Feb. 17, 2022, at 3 p.m. ET.

Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced a collaboration with the NCI to link DecisionDx®-Melanoma testing data with data from the SEER Program's registries.

Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries' Cutaneous Melanoma Cases

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarretsEsophagus--Castle Biosciences announced that it has received a 2022 Top Workplaces USA award from Energage.

Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences will present data highlighting its portfolio of skin cancer tests at Maui Derm for Dermatologists 2022, Jan. 24-28, 2022.

Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of clinical performance study data related to DecisionDx®-SCC in Future Oncology.

Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of a study in Ocular Oncology and Pathology related to the Company's DecisionDx®-UMSeq 7-gene DNA sequencing panel.

Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #2021results--Castle today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2021.

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences is scheduled to present a company overview at the 24th Annual Needham Growth Conference, Jan. 10, 2022, at 12:30 p.m. Eastern time.

Castle Biosciences to Present at the 24th Annual Needham Growth Conference

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarretsEsophagus--Castle Biosciences announced it has completed its acquisition of Cernostics, Inc.

Castle Biosciences Completes Acquisition of Cernostics

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced oral presentations on its DecisionDx® skin cancer tests at the American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting.

Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of data demonstrating that DecisionDx®-Melanoma is a significant independent predictor of metastatic recurrence.

Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Metastatic Recurrence in Stage I-III Cutaneous Melanoma Published in Future Oncology

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BestLedCompany--Castle Biosciences announced that it has been named in Inc.'s first-annual Best-Led Companies list.

Castle Biosciences Named in Inc.'s First-Annual Best-Led Companies

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences has been named a 2021 Houston Chronicle Top Workplace.

Castle Biosciences Named a 2021 Houston Chronicle Top Workplace

The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to its downbeat Q3 results.

What's Next For Castle Biosciences Stock?

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum, Nov. 18, 2021, 9:30 a.m. ET.

Castle Biosciences to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2021 Results - Earnings Call Transcript

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -34.29% and -0.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Lags Revenue Estimates

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle today announced its financial results for the third quarter and nine months ended Sept. 30, 2021.

Castle Biosciences Announces Third Quarter 2021 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences announced the launch of the Company's inaugural Environmental, Social and Governance (ESG) report.

Castle Biosciences Releases Inaugural Environmental, Social and Governance (ESG) Report

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle announced the publication of a study validating performance of the i31-SLNB algorithm to determine sentinel lymph node biopsy positivity risk.

Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences announced its agreement with ModMed to establish an interface with ModMed's electronic health records system, EMA®.

Castle Biosciences' Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle announced that the Company's DecisionDx®-Melanoma integrated test result (ITR) now includes i31-GEP for Risk of Recurrence (i31-ROR).

DecisionDx®-Melanoma Integrated Test Result Now Includes i31-GEP for Risk of Recurrence

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxDiffDxMelanoma--Castle announced a recent poster presentation on its DecisionDx® DiffDx™-Melanoma test at the ASDP 58th Annual Meeting.

News for Castle Biosciences Inc Stock (CSTL)